Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7591019rdf:typepubmed:Citationlld:pubmed
pubmed-article:7591019lifeskim:mentionsumls-concept:C0020538lld:lifeskim
pubmed-article:7591019lifeskim:mentionsumls-concept:C0205145lld:lifeskim
pubmed-article:7591019lifeskim:mentionsumls-concept:C0021655lld:lifeskim
pubmed-article:7591019lifeskim:mentionsumls-concept:C0441712lld:lifeskim
pubmed-article:7591019pubmed:issue5lld:pubmed
pubmed-article:7591019pubmed:dateCreated1995-12-7lld:pubmed
pubmed-article:7591019pubmed:abstractTextMicroalbuminuria in patients with essential hypertension is a marker of incipient glomerular dysfunction and clusters with lipid and hemodynamic abnormalities. Recent evidence has shown that hypertensive patients with microalbuminuria have a hyperinsulinemic response to oral glucose, suggesting the presence of insulin resistance. To directly test this possibility we studied insulin action in two accurately matched groups (n = 10 each) of hypertensive patients with or without microalbuminuria (14 +/- 2 versus 52 +/- 7 mg/24 h-1, mean of three 24-hour collections). In response to glucose ingestion microalbuminuric patients showed slight hyperglycemia (area under the curve, 928 +/- 43 versus 784 +/-19 nmol/L-1/2h-1, P < .02) and a marked hyperinsulinemia (26.8 +/- 3.3 versus 49.8 +/- 3.7 nmol/L-1/2h-1, P < 0.01). Basal arterial blood pressure, heart rate, and forearm blood flow were similar in the two groups and did not change significantly during a 2-hour euglycemic insulin clamp. Insulin-stimulated wholebody glucose uptake was 25% lower in microalbuminuric patients (33.5 +/- 2.5 versus 25.2 +/- 2.1 mumol/min-1/kg-1, P < .02). This difference was entirely due to a 40% reduction in glycogen synthesis (12.9 +/- 1.8 versus 21.3 +/- 3.2 mumol/min-1/kg-1, P < .05) as glucose oxidation was similarly stimulated in the two groups. In contrast there was no difference in the ability of insulin to suppress hepatic glucose production (by approximately 100% at the end of the clamp), to decrease fractional sodium and potassium excretions (by 35%), to lower circulating free fatty acids (by 80%), and to reduce plasma potassium concentrations (by 10%).(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:7591019pubmed:languageenglld:pubmed
pubmed-article:7591019pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7591019pubmed:citationSubsetIMlld:pubmed
pubmed-article:7591019pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7591019pubmed:statusMEDLINElld:pubmed
pubmed-article:7591019pubmed:monthNovlld:pubmed
pubmed-article:7591019pubmed:issn0194-911Xlld:pubmed
pubmed-article:7591019pubmed:authorpubmed-author:FerranniniEElld:pubmed
pubmed-article:7591019pubmed:authorpubmed-author:BianchiSSlld:pubmed
pubmed-article:7591019pubmed:authorpubmed-author:NataliAAlld:pubmed
pubmed-article:7591019pubmed:authorpubmed-author:BigazziRRlld:pubmed
pubmed-article:7591019pubmed:authorpubmed-author:BaldariGGlld:pubmed
pubmed-article:7591019pubmed:authorpubmed-author:PecoriNNlld:pubmed
pubmed-article:7591019pubmed:authorpubmed-author:CiociaroDDlld:pubmed
pubmed-article:7591019pubmed:authorpubmed-author:Quiñones...lld:pubmed
pubmed-article:7591019pubmed:authorpubmed-author:MuscelliEElld:pubmed
pubmed-article:7591019pubmed:issnTypePrintlld:pubmed
pubmed-article:7591019pubmed:volume26lld:pubmed
pubmed-article:7591019pubmed:ownerNLMlld:pubmed
pubmed-article:7591019pubmed:authorsCompleteYlld:pubmed
pubmed-article:7591019pubmed:pagination789-95lld:pubmed
pubmed-article:7591019pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:7591019pubmed:meshHeadingpubmed-meshheading:7591019-...lld:pubmed
pubmed-article:7591019pubmed:meshHeadingpubmed-meshheading:7591019-...lld:pubmed
pubmed-article:7591019pubmed:meshHeadingpubmed-meshheading:7591019-...lld:pubmed
pubmed-article:7591019pubmed:meshHeadingpubmed-meshheading:7591019-...lld:pubmed
pubmed-article:7591019pubmed:meshHeadingpubmed-meshheading:7591019-...lld:pubmed
pubmed-article:7591019pubmed:meshHeadingpubmed-meshheading:7591019-...lld:pubmed
pubmed-article:7591019pubmed:meshHeadingpubmed-meshheading:7591019-...lld:pubmed
pubmed-article:7591019pubmed:meshHeadingpubmed-meshheading:7591019-...lld:pubmed
pubmed-article:7591019pubmed:meshHeadingpubmed-meshheading:7591019-...lld:pubmed
pubmed-article:7591019pubmed:meshHeadingpubmed-meshheading:7591019-...lld:pubmed
pubmed-article:7591019pubmed:meshHeadingpubmed-meshheading:7591019-...lld:pubmed
pubmed-article:7591019pubmed:year1995lld:pubmed
pubmed-article:7591019pubmed:articleTitleInsulin resistance in microalbuminuric hypertension. Sites and mechanisms.lld:pubmed
pubmed-article:7591019pubmed:affiliationNephrology Unit, Spedali Riuniti, Livorno, Italy.lld:pubmed
pubmed-article:7591019pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7591019lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7591019lld:pubmed